natgillin/translations-raw huggingface dataset:
Take special care with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics: 
Eriline ettevaatus on vajalik vaktsiiniga Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics:
Prepandemic Influenza vaccine (H5N1) (surface antigen, inativated, adjuvanted) 
Pre-pandeemiline gripiviiruse vaktsiin (H5N1) (pinnaantigeen, inaktiveeritud, adjuveeritud)
General disorders and administration site conditions Very common: injection site swelling, injection site pain, injection site induration, injection site redness, fatigue 
Väga sage: süstekoha paistetus, süstekoha valu, süstekoha kõvastumine, süstekoha punetus, väsimus Sage: süstekoha ekhümoos, palavik, haiglane olek, külmavärinad Aeg-ajalt: gripisarnane haiglane olek
PHARMACEUTICAL FORM AND CONTENTS Suspension for injection. 
RAVIMVORM JA PAKENDI SUURUS
Day 43 to Day 1 % SC (95% CI) 
% SC (95% usaldusvahemik) 43. päev
There are no data regarding the use of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics during breast-feeding. 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i kasutamise kohta rinnaga toitmise ajal andmed puuduvad.
There are no data with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics using the subcutaneous route. 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i subkutaanse manustamise kohta andmed puuduvad.
Seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibodies to H5N1 A/turkey/Turkey/05 after the 2 
Seroprotektsiooni määr*, serokonversiooni määr* ja serokonversiooni faktor** anti-HA-antikehade suhtes H5N1 A/turkey/Turkey/05-le pärast teist annust täiskasvanutel vanuses 18...60 aastat, määratuna SRH- ja HI-testide põhjal, olid järgmised:
Any 
MUU
Rare: anaphylaxis 
Harv: silmade paistetus
The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use from 6 months of age and with a composition that is similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics): 
Focetria H1N1v (litsentseeritud kasutamiseks alates 6. elukuust, koostis sarnaneb Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'ile) turustamisjärgse jälgimise põhjal on teatatud lisaks ka järgnevate kõrvaltoimete esinemisest:
c) 
A.
What Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics contains 
Mida Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics sisaldab
Study V87P2 Adults booster after 2rd dose 
Uuring V87P2 Täiskasvanud korduvvaktsiin
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Novartis Vaccines & Diagnostics S.r.l. 
Novartis Vaccines & Diagnostics S.r.l.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARDBOARD BOX 
VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
NAME OF THE MEDICINAL PRODUCT Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe. 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics süstesuspensioon eeltäidetud süstlas.
General disorders and administration site conditions Asthenia. 
Üldised häired ja manustamiskoha reaktsioonid Asteenia.
HOW PREPANDEMIC INFLUENZA VACCINE (H5N1) (SURFACE ANTIGEN, INACTIVATED, ADJUVANTED) NOVARTIS VACCINES AND DIAGNOSTICS IS 
Kuidas Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics'i säilitada
It is available as tablets (160 mg/20 mg; 320 mg/40 mg). 
Seda turustatakse tablettidena (160 mg / 20 mg; 320 mg / 40 mg).
Eurartesim is taken once a day for three consecutive days, at the same time each day. 
Eurartesimi võetakse üks kord ööpäevas kolm päeva järjest, iga päev samal kellaajal.
The European Commission granted a marketing authorisation valid throughout the European Union for Eurartesim on 27 October 2011. 
Euroopa Komisjon andis Eurartesimi müügiloa, mis kehtib kogu Euroopa Liidus, 27. oktoobbril 2011.
The tablets may be crushed and mixed with water if needed. 
Tablette tohib vajaduse korral purustada ja segada veega.
The full EPAR for Eurartesim can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Euroopa avaliku hindamisaruande täistekst Eurartesimi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The Eurartesim carton is to include instructions to take the medicine at least 3 hours before or after food. 
Eurartesimi karbil on juhised, et ravimit tuleb võtta vähemalt 3 tundi enne või pärast sööki.
‘Uncomplicated' means the disease does not involve severe, life-threatening symptoms. 
Tüsistusteta tähendab, et haigusega ei kaasne rasked eluohtlikud sümptomid.
The company will also complete a study on Eurartesim's effects on the heart. 
Ettevõte teeb ka Eurartesimi südamemõjude uuringu.
Although the exact way in which it kills the parasite is not fully understood, it is believed to damage the parasite membrane. 
Kuigi täpne mehhanism, kuidas see aine parasiidi hävitab, ei ole teada, arvatakse, et see kahjustab parasiidi membraani.
Other information about Eurartesim 
Muu teave Eurartesimi kohta
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eurartesim have also been included in the summary of product characteristics and the package leaflet. 
Eurartesimi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
It can be used in adults and children aged 6 months and over and weighing 5 kg or more. 
Ravimit tohib kasutada täiskasvanutel ja vähemalt 6-kuustel lastel, kelle kehamass on vähemalt 5 kg.
Artenimol is a derivative of the naturally occurring substance artemisinin. 
Artenimool on looduslikult esineva aine artemisiniini derivaat.
The company that markets Eurartesim will provide all doctors expected to prescribe or use Eurartesim with an educational pack containing important information on the correct use of the medicine, including a checklist of the medicines that Eurartesim must not be given with, to reduce the risk of QTc interval prolongation. 
Eurartesimi turustaja annab kõikidele arstidele, kes eeldatavasti määravad Eurartesimiga ravi või kasutavad seda, teabepakme, mis sisaldab olulist teavet ravimi õige kasutamise kohta, sealhulgas vastunäidustatud samaaegsete ravimite kontroll-loendit, et vähendada QTc-intervalli pikenemise riski.
The dose is determined by the patient's body weight. 
Ravimi annus sõltub patsiendi kehamassist.
The CHMP noted the potential risk for QTc interval prolongation, and included restrictions in the product information to minimise the risk to patients. 
Komitee juhtis tähelepanu võimalikule QTc-intervalli pikenemise riskile ning lisas patsientide riski minimeerimiseks tooteteabesse piirangud.
It must not be used in patients who have or are at risk of QTc interval prolongation or cardiac arrhythmias (unstable heart rhythm) or who are taking medicines that can affect heart rhythm. 
Seda ei tohi kasutada patsiendid, kellel on QTc-intervalli pikenemine või südame rütmihäired või nende risk või kes võtavad ravimeid, mis võivad mõjutada südamerütmi.
In adults, the most common side effects with Eurartesim (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), headache, QTc interval prolongation (an alteration of the electrical activity of the heart, which can cause a life-threatening abnormality of heart rhythm), tachycardia (rapid heartbeat), weakness, and fever. 
Eurartesimi kõige sagedamad kõrvalnähud täiskasvanutel (esinenud 1-10 patsiendil 100st) on aneemia (erütrotsüütide ehk vere punaliblede vähesus), peavalu, QTc-intervalli pikenemine (südame elektrilise talitluse muutus, mis võib põhjustada eluohtlikke südame rütmihäireid), tahhükardia (kiirenenud südametegevus), nõrkus ja palavik.
For more information about treatment with Eurartesim, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Eurartesimiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
This is a summary of the European public assessment report (EPAR) for Eurartesim. 
See on ravimi Eurartesim Euroopa avaliku hindamisaruande kokkuvõte.
What measures are being taken to ensure the safe use of Eurartesim? 
Mis meetmed võetakse, et tagada Eurartesimi kasutamise ohutus?
In children, the most common side effects with Eurartesim (seen in more than 1 patient in 10) were influenza (flu), cough and fever. 
Eurartesimi kõige sagedamad kõrvalnähud lastel (esinenud enam kui 1 patsiendil 10st) on gripp, köha ja palavik.
Eurartesim must not be used in patients with severe malaria. 
Eurartesimi ei tohi kasutada raske malaariaga patsiendid.
Therefore, the Committee concluded that the benefits of Eurartesim outweigh its risks and recommended that it be granted marketing authorisation. 
Seetõttu otsustas komitee, et ravimi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The tablets are swallowed with water when the stomach is empty, at least three hours before or after a meal. 
Tabletid võetakse tühja kõhuga (vähemalt 3 tundi pärast sööki) ja neelatakse koos veega.
The main measure of effectiveness was the proportion of patients who were cured 63 days after treatment. 
Efektiivsuse põhinäitaja oli nende patsientide protsent, kes olid 63 päeva jooksul pärast ravi paranenud.
The Committee noted that Eurartesim meets World Health Organization recommendations for P. falciparum malaria treatment by offering a new alternative artemisinin combination therapy containing two active substances which work in different ways. 
Komitee märkis, et Eurartesim vastab Maailma Terviseorganisatsiooni soovitustele parasiidi Plasmodium falciparum põhjustatud malaaria ravimiseks, sest Eurartesim on uus alternatiivne artemisiniini kombinatsioonravim, mille toimeainete toimemehhanism on erinev.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Eurartesim. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
It is chemically related to other widely available medicines used to treat malaria. 
See on keemiliselt sarnane teiste laialdaselt turustatavate malaariaravimitega.
The main measure of effectiveness was the proportion of patients who were cured 28 days after treatment. 
Efektiivsuse põhinäitaja oli nende patsientide protsent, kes olid 28 päeva jooksul pärast ravi paranenud.
For the full list of all side effects with Eurartesim, see the package leaflet. 
Eurartesimi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
Eurartesim is a malaria medicine that contains the active substances piperaquine tetraphosphate and artenimol. 
Eurartesim on malaariaravim, mis sisaldab toimeainena piperakiintetrafosfaati ja artenimooli.
Why has Eurartesim been approved? 
Miks Eurartesim heaks kiideti?
It is thought to work by blocking a step in the parasite's metabolism needed for its survival. 
Arvatakse, et see blokeerib parasiidi elusolekuks vajaliku ainevahetusetapi.
What is Eurartesim? 
Mis on Eurartesim?
Eurartesim piperaquine tetraphosphate / artenimol 
Eurartesim piperakiintetrafosfaat/artenimool
In the first study, 63 days after treatment 97% of patients who received Eurartesim had been cured, compared with 95% of patients treated with the comparator medicine. 
Esimeses uuringus oli patsiente, kes olid 63 päeva jooksul pärast ravi paranenud, Eurartesimi uuringurühmas 97% ja võrdlusravimi rühmas 95%.
What is the risk associated with Eurartesim? 
Mis riskid Eurartesimiga kaasnevad?
Malaria is an infection caused by a parasite known as Plasmodium and spread through the bite of an infected mosquito. 
Malaariat põhjustab nakatumine parasiidiga Plasmodium, mis levib nakatunud sääskede pistetega.
In the first study, Eurartesim was compared with another malaria medicine containing artesunate and mefloquine in 1,150 patients. 
Esimeses uuringus (1150 patsienti) võrreldi Eurartesimi teise malaariaravimiga, mis sisaldas artesunaati ja meflokiini.
In the second study, Eurartesim was compared with another medicine containing artemether and lumefantrine in 1,553 children. 
Teises uuringus (1553 last) võrreldi Eurartesimi teise malaariaravimiga, mis sisaldas artemeetrit ja lumefantriini.
What benefit has Eurartesim shown during the studies? 
Milles seisneb uuringute põhjal Eurartesimi kasulikkus?
In the second study, 28 days after treatment 93% of patients who received Eurartesim had been cured, compared with 95% of patients treated with the comparator medicine. 
Teises uuringus oli patsiente, kes olid 28 päeva jooksul pärast ravi paranenud, Eurartesimi uuringurühmas 93% ja võrdlusravimi rühmas
How does Eurartesim work? 
Kuidas Eurartesim toimib?
The active substances in Eurartesim, piperaquine tetraphosphate and artenimol, are antimalarial substances which kill the P. falciparum parasite. 
Eurartesimi toimeained dihüdroartemisiniin ja artenimool on malaariaravimid, mis hävitavad parasiidi Plasmodium falciparum.
Piperaquine tetraphosphate is a so-called bisquinolone. 
Piperakiintetrafosfaat on biskinoliin.
Eurartesim is used to treat uncomplicated malaria caused by the Plasmodium falciparum parasite. 
Eurartesimi kasutatakse parasiidi Plasmodium falciparum põhjustatud ja tüsistusteta malaaria raviks.
Eurartesim was investigated in two main studies in patients with uncomplicated P. falciparum malaria. 
Kahes põhiuuringus uuriti Eurartesimi parasiidi Plasmodium falciparum põhjustatud ja tüsistusteta malaariaga patsientidel.
The CHMP considered that Eurartesim had been shown to be effective in treating uncomplicated P. falciparum malaria while the side effects were similar to those seen with comparable treatments. 
Inimravimite komitee järeldas, et uuringutes on tõendatud Eurartesimi efektiivsus parasiidi Plasmodium falciparum põhjustatud ja tüsistusteta malaaria ravimisel ning selle kõrvalnähud on sarnased võrdlusravimite omadega.
How has Eurartesim been studied? 
Kuidas Eurartesimi uuriti?
How is Eurartesim used? 
Kuidas Eurartesimi kasutatakse?
What is Eurartesim used for? 
Milleks Eurartesimi kasutatakse?
Eurartesim was shown to be effective in treating uncomplicated P. falciparum malaria. 
Uuringute põhjal oli Eurartesim parasiidi Plasmodium falciparum põhjustatud ja tüsistusteta malaaria ravimisel efektiivne.
The full EPAR and risk management plan summary for Aripiprazole Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte ravimi Aripiprazole Sandoz kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Its exact mechanism of action is unknown, but it attaches to several different receptors on nerve cells in the brain. 
Aine täpne toimemehhanism ei ole teada, kuid see seondub aju närvirakkude pinnal oleva mitme retseptoriga.
This means that it is similar to a ‘reference medicine', but it contains aripiprazole at a new strength in addition to existing strengths: while the reference medicine, Abilify, is available as 5, 10, 15 and 30 mg, Aripiprazole Sandoz is also available as 20 mg tablets. 
See tähendab, et ravim on sarnane võrdlusravimiga, kuid sisaldab aripiprasooli lisaks olemasolevatele tugevustele ka uues tugevuses: võrdlusravimit Abilify turustatakse tugevustes 5 mg, 10 mg, 15 mg ja 30 mg, ravimit Aripiprazole Sandoz turustatakse ka 20 mg tablettidena.
This means that aripiprazole acts like dopamine and 5-hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters. 
See tähendab, et aripiprasool mõjub nagu dopamiin ja 5hüdroksütrüptamiin, aktiveerides neid retseptoreid, kuid vähem kui neurotransmitterid.
The company provided data from the published literature on aripiprazole. 
Ettevõte esitas aripiprasooli kohta avaldatud kirjandusest pärinevad andmed.
A risk management plan has been developed to ensure that Aripiprazole Sandoz is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada ravimi Aripiprazole Sandoz võimalikult ohutu kasutamine.
The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Sandoz is broken down in the body. 
Annust tuleb kohandada patsientidel, kes võtavad teisi ravimeid, mis mõjutavad ravimi Aripiprazole Sandoz lagunemist organismis.
What measures are being taken to ensure the safe and effective use of Aripiprazole Sandoz? 
Mis meetmed võetakse, et tagada ravimi Aripiprazole Sandoz ohutu ja efektiivne kasutamine?
In this way, aripiprazole helps to change the activity of the nerve cells which are thought to give rise to psychotic or manic symptoms and preventing them from returning. 
Nii aitab aripiprasool muuta nende närvirakkude talitlust, mis tekitavad eeldatavasti psühhoosi- ja maaniasümptomeid, ning ennetab nende sümptomite taasteket.
The Committee recommended that Aripiprazole Sandoz be approved for use in the EU. 
Komitee soovitas ravimi Aripiprazole Sandoz kasutamise Euroopa Liidus heaks kiita.
Because Aripiprazole Sandoz is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Et Aripiprazole Sandoz on võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
What is Aripiprazole Sandoz and what is it used for? 
Mis on Aripiprazole Sandoz ja milleks seda kasutatakse?
Aripiprazole Sandoz is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults whose illness has improved with the medicine in the past. 
Ravimit Aripiprazole Sandoz kasutatakse mõõdukate kuni raskete maaniaepisoodide raviks täiskasvanutel ja uute maaniaepisoodide ennetamiseks täiskasvanutel, kellel on varem tekkinud sellele ravimile ravivastus.
Aripiprazole is thought to act mainly by being a ‘partial agonist' at the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin). 
Arvatakse, et aripiprasool mõjub põhiliselt neurotransmitterite dopamiini ja 5-hüdroksütrüptamiini (serotoniini) retseptorite osalise agonistina.
The company carried out ‘bioequivalence' studies to show that Aripiprazole Sandoz is bioequivalent to the reference medicine, Abilify. 
Ettevõte korraldas bioekvivalentsuse uuringud, et tõendada ravimi Aripiprazole Sandoz bioekvivalentsust võrdlusravimiga Abilify.
Aripiprazole Sandoz is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over. 
Ravimit Aripiprazole Sandoz kasutatakse ka kuni 12 nädalat kestvaks mõõdukate kuni raskete maaniaepisoodide raviks vähemalt 13-aastastel patsientidel.
In addition, when used for patients aged 13 years or older with moderate to severe manic episodes in bipolar I disorder, the company that markets Aripiprazole Sandoz will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in these patients. 
Mõõdukate kuni raskete maaniaepisoodidega vähemalt 13-aastaste I tüüpi bipolaarse häirega patsientide korral annab ravimi Aripiprazole Sandoz tootja patsientidele, nende hooldajatele ja arstidele teabepakme, mis selgitab ravimi ohutut kasutamist nendel patsientidel.
This is a summary of the European public assessment report (EPAR) for Aripiprazole Sandoz. 
See on ravimi Aripiprazole Sandoz Euroopa avaliku hindamisaruande kokkuvõte.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Sandoz has been shown to have comparable quality and to be bioequivalent to Abilify. 
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Aripiprazole Sandoz võrreldav kvaliteet ja bioekvivalentsus ravimiga Abilify.
Aripiprazole Sandoz aripiprazole 
Aripiprazole Sandoz aripiprasool
Aripiprazole Sandoz contains the active substance aripiprazole and is a ‘generic' and a ‘hybrid' medicine. 
Aripiprazole Sandoz sisaldab toimeainena aripiprasooli ning on geneeriline ja hübriidravim.
This disrupts signals transmitted between brain nerve cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other. 
See häirib ajurakkude vahel neurotransmitterite (virgatsainete) vahendatavaid närvisignaale.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati ravimi Aripiprazole Sandoz omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
For practical information about using Aripiprazole Sandoz, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate ravimi Aripiprazole Sandoz kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
For more information about treatment with Aripiprazole Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate ravimiga Aripiprazole Sandoz toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
In patients aged between 15 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Algannus 15-17-aastastel patsientidel on 2 mg ööpäevas (kasutatakse vedelikuna turustatavat aripiprasooli ravimvormi), mida suurendatakse järk-järgult kuni soovitatava annuseni 10 mg üks kord ööpäevas.
It is not intended to provide practical advice on how to use Aripiprazole Sandoz. 
Hindamisaruandes ei anta ravimi Aripiprazole Sandoz kasutamise praktilisi nõuandeid.
Why is Aripiprazole Sandoz approved? 
Miks Aripiprazole Sandoz heaks kiideti?
Aripiprazole Sandoz is used in patients with the following mental illnesses: 
Ravimit Aripiprazole Sandoz kasutatakse järgmiste vaimuhaigustega patsientide raviks.
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Maaniaepisoodide ravi algannus 13-17-aastastel patsientidel on 2 mg ööpäevas (kasutatakse vedelikuna turustatavat aripiprasooli ravimvormi), mida suurendatakse järk-järgult kuni soovitatava annuseni 10 mg üks kord ööpäevas.
Aripiprazole Sandoz is available as tablets and can only be obtained with a prescription. 
Aripiprazole Sandoz on retseptiravim ja seda turustatakse tablettidena.
For schizophrenia, the recommended starting dose is 10 or 15 mg by mouth per day in adults, followed by a ‘maintenance' dose of 15 mg once a day. 
Soovitatav algannus täiskasvanutel skisofreenia ravis suukaudsel manustamisel on 10 mg või 15 mg ööpäevas, millele järgneb säilitusannus 15 mg üks kord ööpäevas.
Other information about Aripiprazole Sandoz 
Muu teave ravimi Aripiprazole Sandoz kohta